Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis - The Baytown Sun Get link Facebook X Pinterest Email Other Apps September 14, 2020 Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis The Baytown Sun Get link Facebook X Pinterest Email Other Apps Comments
Analysis | The Keys to Speed in Race for Vaccine, and Its Perils - Washington Post August 26, 2020 Analysis | The Keys to Speed in Race for Vaccine, and Its Perils Washington Post Read more
Prematurity Awareness Month: Educating the public about Respiratory Syncytial Virus is vital, claims leading consultant - ZAWYA November 20, 2019 Prematurity Awareness Month: Educating the public about Respiratory Syncytial Virus is vital, claims leading consultant ZAWYA Read more
Oishei Children's Hospital Seeing Spike in RSV Cases - Spectrum News December 30, 2019 Oishei Children's Hospital Seeing Spike in RSV Cases Spectrum News Read more
Comments
Post a Comment